---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-021801"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T16:24:30.487177+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Axsome Q4/FY24 revenue $118.8M/$385.7M; Auvelity growth 124% YoY; Symbravo approved; pipeline NDA submissions on track

## Summary
- Total net product revenue FY24 $385.7M (+88%); Q4 $118.8M (+66% YoY).
- Auvelity net sales FY24 $291.4M (+124%); Q4 $92.6M (+89% YoY).
- Symbravo approved Jan 30, 2025 for acute migraine; commercial launch in ~4 months.
- Patent settlement with Teva extends Auvelity generic entry to 2038–2039; license with pediatric exclusivity.
- AXS-05 (Alzheimer's agitation) and AXS-12 (narcolepsy) NDA submissions on track for 2H 2025; AXS-14 NDA submission in 1Q 2025.

## SEC filing metadata
- accession: 0000950170-25-021801
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/0000950170-25-021801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-20250218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-021801
- JSON: https://secwatch.observer/filing/0000950170-25-021801.json
- Plain text: https://secwatch.observer/filing/0000950170-25-021801.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.